This site is for health care professionals only.
Our 4 Bold Approaches to Cancer Treatment

Scientific Presentations

Novartis Presentations at the 2021 ASCO Annual Meeting

All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation.
Abstract # 1054 - Poster

Alpelisib

Long-term (LT) disease control in patients (pts) with hormone receptor–positive (HR+), PIK3CA-altered advanced breast cancer (ABC) treated with alpelisib (ALP) + fulvestrant (FUL)

Lead author:
Dejan Juric
View Abstract
Abstract # 1060 – Poster

Alpelisib

Impact of duration of prior cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) therapy on alpelisib (ALP) benefit in patients (pts) with hormone receptor–positive (HR+), human epidermal growth factor receptor-2–negative (HER2–), PIK3CA-mutated advanced breast cancer (ABC) from BYLieve

Lead author:
Stephen Chia
View Abstract
Abstract # 1001 - Oral

Ribociclib

Updated overall survival (OS) results from the Phase III MONALEESA-3 trial of postmenopausal patients (pts) with hormone receptor positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC) treated with fulvestrant (FUL) ± ribociclib (RIB)

Lead author:
Dennis Slamon
View Abstract
Abstract # 1051 - Poster

Ribociclib

Correlation between work productivity loss (WPL) and European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ-C30) domains from the MONALEESA-7 (ML-7) trial of premenopausal women with HR+/HER2- advanced breast cancer (ABC).

Lead author:
Debu Tripathy
View Abstract
Abstract # e18519 - Publication Only

Patient Related Experience

Do you hear us? Elevating the voice of patients (pts) from Asia Pacific (AP) & Middle East (ME) in pharmaceutical research

Lead author:
Julie Rihani
View Abstract
All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation.
Abstract # 9020 - Poster Discussion

Capmatinib

Capmatinib in 𝘔𝘌𝘛 exon 14-mutated, advanced non-small cell lung cancer (NSCLC): updated results from the GEOMETRY mono-1 study

Lead author:
Juergen Wolf
View Abstract
Abstract # 9048 - Poster

Capmatinib

Phase 1b/2 study of capmatinib plus gefitinib in patients with EGFR-mutated, MET-dysregulated non-small cell lung cancer who received prior therapy: Final overall survival and safety.

Lead author:
Yi-Long Wu
View Abstract
Abstract # 9056 - Poster

Capmatinib

Patient-reported outcomes in capmatinib-treated patients (pts) with METex14- mutated advanced non-small cell lung cancer (NSCLC): results from the Phase II GEOMETRY mono-1 study

Lead author:
Juergen Wolf
View Abstract
Abstract # 9111 - Poster

Capmatinib

Capmatinib efficacy in patients with NSCLC identified as METex14 using an NGS-based liquid biopsy assay: Results from the GEOMETRY mono-1 study.

Lead author:
Rebecca Heist
View Abstract
ABSTRACT #9069 – POSTER

Tislelizumab

The effects of tislelizumab treatment on the health-related quality of life of non-small cell lung cancer patients who progressed on a prior platinum-containing regimen. This trial has been sponsored and conducted by BeiGene.

Lead Author:
Cai Zhou
View Abstract
ABSTRACT #9102 – POSTER

Tislelizumab

RATIONALE-307: Tislelizumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced squamous NSCLC in patients aged ≥ 65. This trial has been sponsored and conducted by BeiGene.

Lead Author:
Jie Wang
View Abstract
Abstract # e18823 - Publication Only

Disease Specific

Novel elements of value in the context of oncology

Lead author:
Kamal-Bahl Sachin
View Abstract
All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation.
Abstract # 9525 - Poster

Dabrafenib + Trametinib

Improved pyrexia-related outcomes associated with an adapted pyrexia adverse event (AE) management algorithm in patients (pts) treated with adjuvant dabrafenib plus trametinib (dab + tram): Primary results of COMBI-APlus.

Lead author:
Victoria Atkinson
View Abstract
Abstract # 9560 - Poster

Spartalizumab

Pyrexia-related outcomes upon application of an adapted pyrexia management algorithm in patients (pts) with BRAF V600–mutant unresectable or metastatic melanoma treated with dabrafenib plus trametinib (DAB + TRAM) in the COMBI-i trial

Lead author:
Paolo Ascierto
View Abstract
Abstract # E18774 - Publication Only

Real-world Evidence

Comprehensive real-world evidence in stage III and IV melanoma – evaluation of a cohort of patients (pts) treated at a Portuguese institution

Lead author:
Ivo Julião
View Abstract
All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation.
Abstract # 4112 - Poster

177Lu-DOTATATE

Final overall survival in the phase 3 NETTER-1 study of lutetium-177-DOTATATE in patients with midgut neuroendocrine tumors.

Lead author:
Jonathan Strosberg
View Abstract
Abstract # 4116 - Poster

177Lu-DOTATATE

Efficacy and safety of 177Lu-DOTATATE in patients (pts) with pancreatic neuroendocrine tumors (pNETs): data from the NETTER-R international, retrospective registry

Lead author:
Dominique Clement
View Abstract
Abstract # 8574 - Poster

Pasireotide

First long-term results on efficacy and safety of long-acting pasireotide in combination with everolimus (EVE) in patients (pts) with advanced carcinoids (NET) of the lung/thymus: Phase II LUNA trial

Lead author
Eric Baudin
View Abstract
All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation.
Abstract # LBA4 - Oral

177Lu-PSMA-617

Phase III study of lutetium-177-PSMA-617 in patients (pts) with metastatic castration-resistant prostate cancer (VISION)

Lead author:
Michael Morris
View Abstract
All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation.

Advanced Solid Tumors

Advanced Solid Tumors

Abstract # 2509 - Poster Discussion

NIS793

Phase Ib study of the anti-TGF-β monoclonal antibody (mAb) NIS793 combined with spartalizumab (PDR001), a PD-1 inhibitor, in patients (pts) with advanced solid tumors

Lead author:
Todd Bauer
View Abstract
Abstract # 3005 - Oral

TNO155

A dose finding study of TNO155, a SHP2 inhibitor, in adults with advanced solid tumors

Lead author:
Irene Braña
View Abstract

Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma

ABSTRACT # 4012 – POSTER DISCUSSION

Tislelizumab

RATIONALE 302: Randomized, Phase III study of tislelizumab vs chemotherapy as second-line treatment for advanced unresectable/metastatic esophageal squamous cell carcinoma. This trial has been sponsored and conducted by BeiGene.

Lead Author:
Lin Shen
View Abstract

Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)

Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)

Abstract # TPS4173 - Poster

NIS793

Phase II study of the anti-TGF-β monoclonal antibody (mAb) NIS793 with and without the PD-1 inhibitor spartalizumab in combination with nab-paclitaxel/gemcitabine (NG) versus NG alone in patients (pts) with first-line metastatic pancreatic ductal adenocarcinoma (mPDAC)

Lead author:
Peter Grell
View Abstract

Microsatellite Instability-High/Mismatch Repair Deficient Solid Tumors

Microsatellite Instability-High/Mismatch Repair Deficient Solid Tumors

ABSTRACT # 2569 – POSTER

Tislelizumab

A Phase II study of tislelizumab monotherapy in patients with previously treated, locally advanced unresectable or metastatic microsatellite instability-high/mismatch repair deficient solid tumors. This trial has been sponsored and conducted by BeiGene.

Lead Author:
Jian Li
View Abstract

PIK3CA-related Overgrowth Spectrum (PROS)

PIK3CA-related Overgrowth Spectrum (PROS)

Abstract # TPS3160 - Poster

Alpelisib

EPIK-P2: A prospective Phase II, double-blind, randomized, placebo-controlled study of alpelisib (ALP) in pediatric and adult patients (Pts) with PIK3CA-related overgrowth spectrum (PROS)

Lead author:
Guillaume Canaud
View Abstract
All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation.
Abstract # 7535 - Poster

Tisagenlecleucel

Comparison of efficacy outcomes between tisagenlecleucel (TISA-CEL) and lisocabtagene maraleucel (LISO-CEL) in patients (pts) with relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL)

Lead author:
Steven Schuster
View Abstract
Abstract # e19537 - Publication Only

Tisagenlecleucel

Safety and efficacy of tisagenlecleucel (TISA-CEL) plus pembrolizumab (PEMBRO) in patients (pts) with relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL): updated Analysis of the Phase Ib PORTIA Study

Lead author:
Ulrich Jaeger
View Abstract
Abstract # e19550 - Publication Only

Tisagenlecleucel

Health care resource use (HRU) by Chimeric antigen receptor T-cell (CAR-T) infusion setting among patients (pts) with relapsed and refractory (r/r) DLBCL – a retrospective cohort study using CMS 100% Medicare database

Lead author:
Jing Zhao
View Abstract
Abstract # e19551 - Publication Only

Tisagenlecleucel

Estimating costs of adverse events (AEs) and healthcare resource use (HRU) in patients (pts) with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL) receiving tisagenlecleucel (TISA-CEL) and axicabtagene ciloleucel (AXI-CEL): a summary of real-world evidence

Lead author:
Hongbo Yang
View Abstract
All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation.
Abstract # 7508 - Oral

Tisagenlecleucel

Efficacy and safety of tisagenlecleucel (TISA-CEL) in adult patients (pts) with relapsed/refractory follicular lymphoma (r/r FL): primary analysis of the Phase II ELARA Trial

Lead author:
Stephen Schuster
View Abstract
All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation.
Abstract # e19034 - Publication Only

Sabatolimab

Treatments and outcomes for patients (pts) with myelodysplastic syndrome (MDS) by revised international prognostic scoring system (IPSS-R) scores at the Huntsman Cancer Institute (HCI)

Lead author:
Connor Willis
View Abstract